CN110035743A - 一种Talazoparib药物组合物及其应用 - Google Patents

一种Talazoparib药物组合物及其应用 Download PDF

Info

Publication number
CN110035743A
CN110035743A CN201780011152.3A CN201780011152A CN110035743A CN 110035743 A CN110035743 A CN 110035743A CN 201780011152 A CN201780011152 A CN 201780011152A CN 110035743 A CN110035743 A CN 110035743A
Authority
CN
China
Prior art keywords
talazoparib
weight
parts
acid
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780011152.3A
Other languages
English (en)
Other versions
CN110035743B (zh
Inventor
甘勇
朱全垒
郭仕艳
朱春柳
张馨欣
宋文艺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN110035743A publication Critical patent/CN110035743A/zh
Application granted granted Critical
Publication of CN110035743B publication Critical patent/CN110035743B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种包含PARP抑制剂Talazoparib的药物组合物及其用于治疗肿瘤的用途,所述组合物具体包含(重量份):Talazoparib 0.1‑200，释放速率调节用辅料0.1‑500,小分子调节剂0‑1000,药用可注射溶剂0‑2000。所述组合物可持续维持Talazoparib在体内的有效血药浓度和PARP酶活性抑制水平。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201780011152.3A 2016-12-16 2017-12-15 一种Talazoparib药物组合物及其应用 Active CN110035743B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611170105.7A CN108210461A (zh) 2016-12-16 2016-12-16 一种Talazoparib药物组合物及其应用
CN2016111701057 2016-12-16
PCT/CN2017/116573 WO2018108163A1 (zh) 2016-12-16 2017-12-15 一种Talazoparib药物组合物及其应用

Publications (2)

Publication Number Publication Date
CN110035743A true CN110035743A (zh) 2019-07-19
CN110035743B CN110035743B (zh) 2022-04-08

Family

ID=62557987

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611170105.7A Pending CN108210461A (zh) 2016-12-16 2016-12-16 一种Talazoparib药物组合物及其应用
CN201780011152.3A Active CN110035743B (zh) 2016-12-16 2017-12-15 一种Talazoparib药物组合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201611170105.7A Pending CN108210461A (zh) 2016-12-16 2016-12-16 一种Talazoparib药物组合物及其应用

Country Status (2)

Country Link
CN (2) CN108210461A (zh)
WO (1) WO2018108163A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067840A1 (zh) * 2022-09-30 2024-04-04 上海济煜医药科技有限公司 一种脂质体及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246836B2 (en) * 2018-05-17 2022-02-15 Bluelight Pharmatech Co., Ltd. Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
US20230201122A1 (en) * 2021-12-23 2023-06-29 Boston Scientific Medical Device Limited Chemoembolic compositions and methods of treatment using them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171214A (zh) * 2008-08-06 2011-08-31 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
WO2015192014A1 (en) * 2014-06-13 2015-12-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20150366882A1 (en) * 2011-02-03 2015-12-24 Pop Test Oncology Limited Liability Company System and Method for Diagnosis and Treatment
WO2016130546A1 (en) * 2015-02-10 2016-08-18 Memorial Sloan Kettering Cancer Center Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171214A (zh) * 2008-08-06 2011-08-31 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US20150366882A1 (en) * 2011-02-03 2015-12-24 Pop Test Oncology Limited Liability Company System and Method for Diagnosis and Treatment
WO2015192014A1 (en) * 2014-06-13 2015-12-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2016130546A1 (en) * 2015-02-10 2016-08-18 Memorial Sloan Kettering Cancer Center Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JODI BELZ ET AL: "《https://cancerres.aacrjournals.org/content/76/14_Supplement/3900》", 31 July 2016 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067840A1 (zh) * 2022-09-30 2024-04-04 上海济煜医药科技有限公司 一种脂质体及其制备方法和应用

Also Published As

Publication number Publication date
CN110035743B (zh) 2022-04-08
WO2018108163A1 (zh) 2018-06-21
CN108210461A (zh) 2018-06-29

Similar Documents

Publication Publication Date Title
US10912763B2 (en) Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
JP6574228B2 (ja) 局所麻酔薬のデポー製剤及びその調製方法
JP4814107B2 (ja) 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
EP3160444B1 (en) A pharmaceutical oil-in-water nano-emulsion
US20100098735A1 (en) Injectable depot compositions and its process of preparation
CN110381975A (zh) 一种硼替佐米药物组合物及其应用
Zhang et al. Design of controlled release PLGA microspheres for hydrophobic fenretinide
CN110035743A (zh) 一种Talazoparib药物组合物及其应用
Pachis et al. Sustained release of intravitreal flurbiprofen from a novel drug-in-liposome-in-hydrogel formulation
CN108289832A (zh) 用于以输注或注射形式进行静脉给药的左西孟旦以及输注浓缩液的改善配方
US11400048B2 (en) Pharmaceutical oil-in-water nano-emulsion
US20210401775A1 (en) A liquid injectable composition
Motawee et al. Lipospheres and Pro-Nanolipospheres: Advancements in Drug Delivery Systems
Tamilvanan Oil-in-water nanosized emulsions: medical applications
KR20240096358A (ko) 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법
CN117715625A (zh) 用于治疗晶体和非晶体相关急性炎症性关节炎的包含秋水仙碱的关节内注射用剂型
Nikam et al. Available through Online Review Article www. ijptonline. com

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant